BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

WALGREENS #04517, Original Pharmacy Permit No. PHY 53062; and

WALGREENS #02445, Non-Resident Pharmacy Permit No. NRP 1949; and

WALGREENS #21147, Non-Resident Pharmacy Permit No. NRP 2073,

Respondents

Agency Case No. 6906

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Reproval is hereby

adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this

matter.

This Decision shall become effective at 5:00 p.m. on July 28, 2021.

It is so ORDERED on June 28, 2021.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

By

Seung W. Oh, Pharm.D. Board President

1	MATTHEW RODRIQUEZ	
2	Acting Attorney General of California DIANN SOKOLOFF	
3	Supervising Deputy Attorney General ASPASIA A. PAPAVASSILIOU	
4	Deputy Attorney General State Bar No. 196360	
5	1515 Clay Street, 20th Floor P.O. Box 70550	
6	Oakland, CA 94612-0550 Telephone: (510) 879-0818	
7	Facsimile: (510) 622-2270 Attorneys for Complainant	
8	DEDOD	
9	BEFOR BOARD OF P	
10	DEPARTMENT OF CO STATE OF C	
11		
12	In the Matter of the Accusation Against:	Case No. 6906
13	WALGREENS #04517	STIPULATED SETTLEMENT AND
14	2600 Mowry Ave. Fremont, CA 94538	DISCIPLINARY ORDER FOR PUBLIC REPROVAL
15	Original Pharmacy	[Bus. & Prof. Code § 495]
16	Permit No. PHY 53062,	
17	WALGREENS #02445 8337 S. Park Circle	
18	Orlando, FL 32819	
19	Non-Resident Pharmacy Permit No. NRP 1949,	
20	and	
21	WALGREENS #21147	
22	2225 S. Price Road Chandler, AZ 85286	
23	Non-Resident Pharmacy	
24	Permit No. NRP 2073	
25	Respondents.	
26	IT IS HERERV STIDIII ATED AND AGD	EED by and between the parties to the above-
27	entitled proceedings that the following matters are	•
28		
		1 T & DISC ORDER FOR PUBLIC REPROVAL (6906)

1	PARTIES
2	1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
3	(Board). She brought this action solely in her official capacity and is represented in this matter by
4	Xavier Becerra, Attorney General of the State of California, by Aspasia A. Papavassiliou, Deputy
5	Attorney General.
6	2. Respondent Walgreens #04517, Respondent Walgreens #02445, and Respondent
7	Walgreens #21147 are represented in this proceeding by attorney Sweta H. Patel, whose address
8	is: Klein, Hockel, Iezza & Patel, P.C., 1981 North Broadway, Suite 220, Walnut Creek, CA
9	94596-3877.
10	JURISDICTION
11	3. On or about December 31, 2014, the Board of Pharmacy issued Original Pharmacy
12	Permit Number PHY 53062 to Walgreens #04517 (Respondent Walgreens #04517). The Original
13	Pharmacy Permit was in full force and effect at all times relevant to the charges brought in
14	Accusation No. 6906 and will expire on December 1, 2021, unless renewed.
15	4. On or about March 13, 2017, the Board of Pharmacy issued Non-Resident Pharmacy
16	Permit Number NRP 1949 to Walgreens #02445 (Respondent Walgreens #02445). The Non-
17	Resident Pharmacy Permit was in full force and effect at all times relevant to the charges brought
18	Accusation No. 6906 and will expire on March 1, 2022, unless renewed.
19	5. On or about December 21, 2017, the Board of Pharmacy issued Non-Resident
20	Pharmacy Permit Number NRP 2073 to Walgreens #21147 (Respondent Walgreens #21147).
21	The Non-Resident Pharmacy Permit was in full force and effect at all times relevant to the
22	charges brought in Accusation No. 6906 will expire on December 1, 2021, unless renewed.
23	6. Accusation No. 6906 was filed before the Board of Pharmacy (Board), Department of
24	Consumer Affairs and is currently pending against Respondents. The Accusation and all other
25	statutorily required documents were properly served on Respondents on August 4, 2020.
26	Respondents timely filed their Notice of Defense contesting the Accusation. A copy of
27	Accusation No. 6906 is attached as exhibit A and incorporated by reference.
28	
	2
	STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6906)

1	ADVISEMENT AND WAIVERS
2	7. Respondents have carefully read, fully discussed with counsel, and understand the
3	charges and allegations in Accusation No. 6906. Respondents have also carefully read, fully
4	discussed with counsel, and understand the effects of this Stipulated Settlement and Disciplinary
5	Order for Public Reproval.
6	8. Respondents are fully aware of their legal rights in this matter, including the right to a
7	hearing on the charges and allegations in the Accusation; the right to be represented by counsel at
8	their own expense; the right to confront and cross-examine the witnesses against them; the right
9	to present evidence and to testify on their own behalf; the right to the issuance of subpoenas to
10	compel the attendance of witnesses and the production of documents; the right to reconsideration
11	and court review of an adverse decision; and all other rights accorded by the California
12	Administrative Procedure Act and other applicable laws.
13	9. Respondents voluntarily, knowingly, and intelligently waive and give up each and
14	every right set forth above.
15	<u>CULPABILITY</u>
16	10. Respondents understand and agree that the charges and allegations in Accusation No.
17	6906, if proven at a hearing, constitute cause for imposing discipline upon their Original Permit
18	and Non-Resident Pharmacy Permits.
19	11. For the purpose of resolving the Accusation without the expense and uncertainty of
20	further proceedings, Respondents agree that, at a hearing, Complainant could establish a factual
21	basis for the charges in the Accusation, and that Respondents hereby give up their right to contest
22	those charges.
23	12. Respondents agree that their Original Permit and Non-Resident Pharmacy Permits are
24	subject to discipline and they agree to be bound by the Disciplinary Order below.
25	13. If, however, a subsequent Accusation is filed against any of the Respondents alleging
26	similar violations as alleged in Accusation No. 6906, then the charges and allegations in
27	Accusation No. 6906 shall be deemed to be true and correct regarding the Respondent(s).
28	
	3
	STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6906)

1	RESERVATION
2	14. The admissions made by Respondents in this stipulation are only for the purposes of
3	this proceeding, or any other proceedings in which the Board or other professional licensing
4	agency is involved, and shall not be admissible in any other criminal or civil proceeding.
5	<u>CONTINGENCY</u>
6	15. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents
7	understand and agree that counsel for Complainant and the staff of the Board of Pharmacy may
8	communicate directly with the Board regarding this stipulation and settlement, without notice to
9	or participation by Respondents or their counsel. By signing the stipulation, Respondents
10	understand and agree that they may not withdraw their agreement or seek to rescind the
11	stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this
12	stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order for Public
13	Reproval shall be of no force or effect, except for this paragraph, it shall be inadmissible in any
14	legal action between the parties, and the Board shall not be disqualified from further action by
15	having considered this matter.
16	16. The parties understand and agree that Portable Document Format (PDF) and facsimile
17	copies of this Stipulated Settlement and Disciplinary Order for Public Reproval, including PDF
18	and facsimile signatures thereto, shall have the same force and effect as the originals.
19	17. This Stipulated Settlement and Disciplinary Order for Public Reproval is intended by
20	the parties to be an integrated writing representing the complete, final, and exclusive embodiment
21	of their agreement. It supersedes any and all prior or contemporaneous agreements,
22	understandings, discussions, negotiations, and commitments (written or oral). This Stipulated
23	Settlement and Disciplinary Order for Public Reproval may not be altered, amended, modified,
24	supplemented, or otherwise changed except by a writing executed by an authorized representative
25	of each of the parties.
26	18. In consideration of the foregoing admissions and stipulations, the parties agree that
27	the Board may, without further notice or formal proceeding, issue and enter the following
28	Disciplinary Order:
	4
	STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6906)

1	DISCIPLINARY ORDER	
2	IT IS HEREBY ORDERED that Original Permit No. PHY 53062 issued to Respondent	
3	Walgreens #04517, Non-Residency Pharmacy Permit No. 1949 issued to Respondent Walgreens	
4	#02445, and Non-Resident Pharmacy Permit No. 2073 issued to Respondent Walgreens #21147,	
5	shall be publicly reproved by the Board of Pharmacy under Business and Professions Code	
6	section 495 in resolution of Accusation No. 6906, attached as exhibit A.	
7	Cost Recovery. Respondents shall pay, jointly and severally, a total of \$6,928.75 to the	
8	Board for its costs associated with the investigation and enforcement of this matter. Respondent	
9	shall be permitted to pay these costs in a payment plan approved by the Board. If Respondent	
10	fails to pay the Board costs as ordered, Respondent shall not be allowed to renew their Original	
11	Permit and Non-Resident Pharmacy Permits until Respondent pays costs in full.	
12	Full Compliance. As a resolution of the charges in Accusation No. 6906, this stipulated	
13	settlement is contingent upon Respondent's full compliance with all conditions of this Order. If	
14	Respondent fails to satisfy any of these conditions, such failure to comply constitutes cause for	
15	discipline, including outright revocation, of Original Permit No. PHY 53062 issued to	
16	Respondent Walgreens #04517, Non-Residency Pharmacy Permit No. 1949 issued to Respondent	
17	Walgreens #02445, and Non-Resident Pharmacy Permit No. 2073 issued to Respondent	
18	Walgreens #21147.	
19	ACCEPTANCE	
20	I have carefully read the above Stipulated Settlement and Disciplinary Order for Public	
21	Reproval and have fully discussed it with attorney Sweta H. Patel. I am authorized to sign for	
22	Respondents Walgreens #04517, Walgreens #02445, and Walgreens # 21147 and I understand the	
23	stipulation and the effect it will have on their Original Permit and Non-Resident Pharmacy	
24	Permits. On behalf of the Respondents, I enter into this Stipulated Settlement and Disciplinary	
25	///	
26	///	
27	///	
28		
	5	
	STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6906)	

1	Order for Public Reproval voluntarily, knowingly, and intelligently, and agree to be bound by the	
2	Decision and Order of the Board of Pharmacy.	
3	∇Q_{i}	
4	DATED: 3/24/2021 (ma Khah	
5	Rina Shah, Pharm.D., as Vice President, Pharmacy Operations, for:	
6	WALGREENS #04517 WALGREENS #02445	
7	WALGREENS #21147 Respondents	
8	Respondents	
9	I have read and fully discussed with an authorized representative of Respondent Walgreens	
10	#04517, Respondent Walgreens #02445, and Respondent Walgreens #21147, the terms and	
11	conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order	
12	for Public Reproval. I approve its form and content.	
13		
14	DATED: March 25, 2021 SWETA H. PATEL	
15	Attorney for Respondents	
16		
17	<u>ENDORSEMENT</u>	
18	The foregoing Stipulated Settlement and Disciplinary Order for Public Reproval is hereby	
19	respectfully submitted for consideration by the Board of Pharmacy of the Department of	
20	Consumer Affairs.	
21	DATED: March 26, 2021 Respectfully submitted,	
22	XAVIER BECERRA	
23 24	Attorney General of California DIANN SOKOLOFF	
24 25	Supervising Deputy Attorney General	
23 26	Aspetho	
20	ASPASIA A. PAPAVASSILIOU Deputy Attorney General	
28	Attorneys for Complainant OK2020900061 91349308.docx	
	6	
	STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6906)	

Exhibit A

Accusation No. 6906

1 2 3 4 5 6 7 8	XAVIER BECERRA Attorney General of California DIANN SOKOLOFF Supervising Deputy Attorney General ASPASIA A. PAPAVASSILIOU Deputy Attorney General State Bar No. 196360 1515 Clay Street, 20th Floor P.O. Box 70550 Oakland, CA 94612-0550 Telephone: (510) 879-0818 Facsimile: (510) 622-2270 E-mail: Aspasia.Papavassiliou@doj.ca.gov Attorneys for Complainant	
9	BEFOR	
10	BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA	
11	STATE OF C.	
12		
13	In the Matter of the Accusation Against:	Case No. 6906
14	WALGREENS #04517 2600 Mowry Ave. Fremont, CA 94538	ACCUSATION
15		ACCUSATION
16	Original Pharmacy Permit No. PHY 53062,	
17 18	WALGREENS #02445 8337 S. Park Circle Orlando, FL 32819	
19 20	Non-Resident Pharmacy Permit No. NRP 1949,	
21	and	
22	WALGREENS #21147 2225 S. Price Road	
23	Chandler, AZ 85286	
24	Non-Resident Pharmacy Permit No. NRP 2073	
25	Respondents.	
26	Kespondents.	
27		
28		
		1
	(WALGREENS #04517, WALGREEN	IS #02445, and WALGREENS #21147) ACCUSATION

1	PARTIES
2	1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity
3	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.
4	2. On or about December 31, 2014, the Board of Pharmacy issued Original Pharmacy
5	Permit Number PHY 53062 to Walgreens #04517 (Respondent Walgreens #04517). The Original
6	Pharmacy Permit was in full force and effect at all times relevant to the charges brought in this
7	Accusation and will expire on December 1, 2020, unless renewed.
8	3. On or about March 13, 2017, the Board of Pharmacy issued Non-Resident Pharmacy
9	Permit Number NRP 1949 to Walgreens #02445 (Respondent Walgreens #02445). The Non-
10	Resident Pharmacy Permit was in full force and effect at all times relevant to the charges brought
11	in this Accusation and will expire on March 1, 2021, unless renewed.
12	4. On or about December 21, 2017, the Board of Pharmacy issued Non-Resident
13	Pharmacy Permit Number NRP 2073 to Walgreens #21147 (Respondent Walgreens #21147).
14	The Non-Resident Pharmacy Permit was in full force and effect at all times relevant to the
15	charges brought in this Accusation will expire on December 1, 2020, unless renewed.
16	JURISDICTION
17	5. This Accusation is brought before the Board of Pharmacy (Board), Department of
18	Consumer Affairs, under the authority of the following laws. All section references are to the
19	Business and Professions Code (Code) unless otherwise indicated.
20	6. Section 4300 of the Code states, in pertinent part:
21	(a) Every license issued may be suspended or revoked.
22	(b) The board shall discipline the holder of any license issued by the board,
23	whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
24	(1) Suspending judgment.
25	(2) Placing him or her upon probation.
26	(3) Suspending his or her right to practice for a period not exceeding one year.
27	(4) Revoking his or her license.
28	(5) Taking any other action in relation to disciplining him or her as the board in
	2
	(WALGREENS #04517, WALGREENS #02445, and WALGREENS #21147) ACCUSATION

1	its discretion may deem proper.
1	
2 3	(e) The proceedings under this article shall be conducted in accordance with Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the
4	Government Code, and the board shall have all the powers granted therein. The action shall be final, except that the propriety of the action is subject to review by the
5	superior court pursuant to Section 1094.5 of the Code of Civil Procedure.
6	7. Section 4300.1 of the Code states:
7	The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a
8 9	licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.
10	STATUTORY PROVISIONS
11	8. Section 4301 of the Code states, in pertinent part:
12	The board shall take action against any holder of a license who is guilty of
13	unprofessional conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:
14	
15 16	(d) The clearly excessive furnishing of controlled substances in violation of subdivision (a) of Section 11153 of the Health and Safety Code.
17	(o) Violating or attempting to violate, directly or indirectly, or assisting in or
18	abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy,
19 20	including regulations established by the board or by any other state or federal regulatory agency.
21	9. Section 11153 of the Health and Safety Code states, in pertinent part:
22	(a) A prescription for a controlled substance shall only be issued for a
23	legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice. The responsibility for the proper prescribing and
24	dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.
25	Except as authorized by this division, the following are not legal prescriptions: (1) an order purporting to be a prescription which is issued not in the usual course of
26	professional treatment or in legitimate and authorized research
27	
28	
	3
	(WALGREENS #04517, WALGREENS #02445, and WALGREENS #21147) ACCUSAT

1	REGULATORY PROVISIONS
2	10. California Code of Regulations, title 16, section 1761, states:
3	(a) No pharmacist shall compound or dispense any prescription which contains
4	any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.
5	(b) Even after conferring with the prescriber, a pharmacist shall not compound
6 7	or dispense a controlled substance prescription where the pharmacist knows or has objective reason to know that said prescription was not issued for a legitimate medical purpose.
8	COST RECOVERY
9	11. Section 125.3 of the Code states, in pertinent part, that the Board may request the
10	administrative law judge to direct a licentiate found to have committed a violation or violations of
11	the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
12	enforcement of the case.
13	DRUGS
14	12. Eszopiclone, also known by the brand name Lunesta, is used to treat insomnia. It is a
15	dangerous drug per Business and Professions Code section 4022 and a Scheduled IV controlled
16	substance per Code of Federal Regulations, title 21, section 1308.14, subdivision (c)(55). The
17	maximum dose is 3 mg in a 24-hour period.
18	13. Zolpidem, also known by the brand name Ambien, is used to treat insomnia. It is a
19	dangerous drug per Business and Professions Code section 4022 and a Schedule IV controlled
20	substance per Health and Safety Code section 11057, subdivision (d)(32). The maximum dose is
21	10 mg in a 24-hour period. Zolpidem should be limited to short-term use, as long-term use can
22	result in dependence, abuse, or tolerance.
23	FACTUAL BACKGROUND
24	14. From on or about November 19, 2017, to on or about May 15, 2019, at the Walgreens
25	#04517 pharmacy in Fremont, California, Respondents dispensed eszopiclone and zolpidem to
26	patient L.O. on the below listed occasions.
27	A. On or about November 19, 2017, Respondents dispensed 30 tablets of 3 mg
28	eszopiclone pursuant to Prescription No. 3348061;
	4
	(WALGREENS #04517, WALGREENS #02445, and WALGREENS #21147) ACCUSATION

1	B.	On or about November 22, 2017, Respondents dispensed 30 tablets of 10 mg
2	zolpidem pu	ursuant to Prescription No. 3351125;
3	C.	On or about December 31, 2017, Respondents dispensed 20 tablets of 5 mg zolpidem
4	pursuant to	Prescription No. 3379983;
5	D.	On or about January 8, 2018, Respondents dispensed 30 tablets of 10 mg zolpidem
6	pursuant to	Prescription No. 3386036;
7	E.	On or about February 9, 2018, Respondents dispensed 30 tablets of 10 mg zolpidem
8	pursuant to	Prescription No. 3411616;
9	F.	On or about February 28, 2018, Respondents dispensed 30 tablets of 10 mg zolpidem
10	pursuant to	Prescription No. 3425704;
11	G.	On or about March 14, 2018, Respondents dispensed 10 tablets of 3 mg eszopiclone
12	pursuant to	Prescription No. 3436166;
13	H.	On or about May 10, 2018, Respondents dispensed 30 tablets of 10 mg zolpidem
14	pursuant to	Prescription No. 3476954;
15	I.	On or about June 9, 2018, Respondents dispensed 10 tablets of 3 mg eszopiclone
16	pursuant to	Prescription No. 3497963;
17	J.	On or about June 23, 2018, Respondents dispensed 30 tablets of 10 mg zolpidem
18	pursuant to	Prescription No. 3506988; and
19	К.	On or about May 15, 2019, Respondents dispensed 30 tablets of 3 mg eszopiclone
20	pursuant to	Prescription No. 3726027.
21	15.	Respondents dispensed the above prescriptions despite several red flags or factors of
22	irregularity.	L.O. obtained prescriptions for eszopiclone and zolpidem from multiple prescribers
23	and filled th	em at various Walgreens Pharmacy locations. Furthermore, L.O. mostly received
24	prescription	s for the highest doses of two drugs that are generally used for the same purpose and
25	considered of	duplicate therapy. L.O. also obtained multiple early refills and/or was filling the two
26	medications	in close succession to one another. Finally, L.O. paid for the majority of the
27	prescription	s by using cash or a discount card. The pharmacists at Walgreens #04517 failed to
28	appropriatel	y scrutinize L.O.'s patient profile and recognize the aforementioned factors of
		5
		(WALGREENS #04517, WALGREENS #02445, and WALGREENS #21147) ACCUSATION

irregularity

16. Respondents Walgreens #02445 and #21147 contributed to the improper dispensing 2 of the prescriptions by having a multi-step verification process where multiple pharmacists were 3 involved in the dispensing of one controlled substance prescription. Moreover, the Drug 4 5 Utilization Review (DUR) pharmacists at Walgreens #02445 and #21147 were not licensed in California, and thus did not have access to CURES, but Walgreens #02445 and #2117 required 6 those pharmacists to participate in the verification process of controlled substances, even though 7 8 the pharmacists were unable to determine whether patients were doctor or pharmacy shopping or 9 obtaining early fills of their controlled substances at pharmacies other than Walgreens. 10 FIRST CAUSE FOR CAUSE FOR DISCIPLINE (Unprofessional Conduct: Clearly Excessive Furnishing of Controlled Substances) 11 17. Respondents Walgreens #04517, Walgreens #02445, and Walgreens #21147, are 12 subject to disciplinary action for unprofessional conduct under Code section 4301, subdivision 13 14 (d), due to excessive furnishing of controlled substances in violation of Health and Safety Code section 11153. The circumstances are set forth in paragraphs 14-16, above. 15 SECOND CAUSE FOR DISCIPLINE 16 (Unprofessional Conduct: Violation of Regulation--Erroneous or Uncertain Prescriptions) 17 Respondents Walgreens #04517, Walgreens #02445, and Walgreens #21147, are 18. 18 19 subject to disciplinary action for unprofessional conduct under Code section 4301, subdivision (o), due to violation of a Board regulation. Specifically, Respondents violated California Code of 2021 Regulations, title 16, section 1761, in that they dispensed erroneous or uncertain prescriptions. The circumstances are set forth in paragraphs 14-16, above. 22 **DISCIPLINARY CONSIDERATIONS** 23 24 19. As disciplinary considerations, Respondent further alleges that Walgreens #04517 has been the subject of a Board citation and a public reproval, as described below. 25 On or about July 16, 2018, the Board issued Citation No. CI 2017 77833, now final, 26 A. to Respondent Walgreens #04517 for variation from a prescription in violation of California Code 27 of Regulations, title 16, section 1716. This citation did not impose a fine, but the same 28 6 (WALGREENS #04517, WALGREENS #02445, and WALGREENS #21147) ACCUSATION

1	prescription variation incident previously led to the issuance of Citation No. CI 2016 74001 on or	
2	about January 16, 2018, against Respondent Walgreens #02445, and that citation required	
3	payment of a \$1,500.00 fine, which was paid.	
4	B. In a final Board decision and order effective on or about July 25, 2019, Respondent	
5	Walgreens #04517 was publicly reproved under Business and Professions Code section 495, in	
6	resolution of Accusation No. 6325. The Accusation alleged that Respondent Walgreens #04517	
7	permitted an unlicensed person to act as a pharmacist, failed to place a Pharmacist-in-Charge in	
8	charge of the pharmacy, dispensed medication pursuant to non-compliant prescriptions, failed to	
9	provide records, and failed to identify a licensed pharmacist to verify prescriptions.	
10	PRAYER	
11	WHEREFORE, Complainant requests that a hearing be held on the matters alleged in this	
12	Accusation, and that following the hearing, the Board of Pharmacy issue a decision:	
13	1. Revoking or suspending Original Pharmacy Permit Number PHY 53062, issued to	
14	Walgreens #04517;	
15	2. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 1949, issued	
16	to Walgreens #02445;	
17	3. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 2073, issued	
18	to Walgreens #21147;	
19	4. Ordering Walgreens #04517, Walgreens #02445 and Walgreens #21147 to pay the	
20	Board of Pharmacy the reasonable costs of the investigation and enforcement of this case,	
21	pursuant to Business and Professions Code section 125.3; and,	
22	5. Taking such other and further action as deemed necessary and proper.	
23		
24	DATED: July 29, 2020 Anne Sodergren ANNE SODERGREN	
25	Executive Officer	
26	Board of Pharmacy Department of Consumer Affairs State of California	
27	State of California Complainant	
28	OK2020900061 91244997.docx	
	7	
	(WALGREENS #04517, WALGREENS #02445, and WALGREENS #21147) ACCUSATION	